Phathom Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced the withdrawal of the previously announced, proposed primary and secondary public offering.
October 27, 2021
· 3 min read